- Home
- CHRS vs FLL Comparison
CHRS vs FLL Comparison
Compare CHRS & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FLL
- Stock Information
- Founded
- CHRS 2010
- FLL 1987
- Country
- CHRS United States
- FLL United States
- Employees
- CHRS N/A
- FLL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FLL Hotels/Resorts
- Sector
- CHRS Health Care
- FLL Consumer Discretionary
- Exchange
- CHRS Nasdaq
- FLL Nasdaq
- Market Cap
- CHRS 185.5M
- FLL 156.6M
- IPO Year
- CHRS 2014
- FLL 1993
- Fundamental
- Price
- CHRS $1.52
- FLL $4.15
- Analyst Decision
- CHRS Strong Buy
- FLL Buy
- Analyst Count
- CHRS 4
- FLL 3
- Target Price
- CHRS $5.38
- FLL $6.67
- AVG Volume (30 Days)
- CHRS 10.1M
- FLL 212.7K
- Earning Date
- CHRS 11-06-2024
- FLL 11-06-2024
- Dividend Yield
- CHRS N/A
- FLL N/A
- EPS Growth
- CHRS N/A
- FLL N/A
- EPS
- CHRS N/A
- FLL N/A
- Revenue
- CHRS $304,340,000.00
- FLL $279,132,000.00
- Revenue This Year
- CHRS $1.64
- FLL $24.43
- Revenue Next Year
- CHRS $16.98
- FLL $12.32
- P/E Ratio
- CHRS N/A
- FLL N/A
- Revenue Growth
- CHRS 44.19
- FLL 28.57
- 52 Week Low
- CHRS $0.66
- FLL $3.98
- 52 Week High
- CHRS $3.70
- FLL $5.98
- Technical
- Relative Strength Index (RSI)
- CHRS 52.47
- FLL 22.97
- Support Level
- CHRS $1.45
- FLL $4.45
- Resistance Level
- CHRS $1.85
- FLL $4.30
- Average True Range (ATR)
- CHRS 0.23
- FLL 0.15
- MACD
- CHRS -0.03
- FLL -0.04
- Stochastic Oscillator
- CHRS 3.88
- FLL 3.12
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.